---
reference_id: "PMID:24129063"
title: NRAS mutation is the sole recurrent somatic mutation in large congenital melanocytic nevi.
authors:
- Charbel C
- Fontaine RH
- Malouf GG
- Picard A
- Kadlub N
- El-Murr N
- How-Kit A
- Su X
- "Coulomb-L'Hermine A"
- Tost J
- Mourah S
- Aractingi S
- Guégan S
journal: J Invest Dermatol
year: '2014'
doi: 10.1038/jid.2013.429
content_type: abstract_only
---

# NRAS mutation is the sole recurrent somatic mutation in large congenital melanocytic nevi.
**Authors:** Charbel C, Fontaine RH, Malouf GG, Picard A, Kadlub N, El-Murr N, How-Kit A, Su X, Coulomb-L'Hermine A, Tost J, Mourah S, Aractingi S, Guégan S
**Journal:** J Invest Dermatol (2014)
**DOI:** [10.1038/jid.2013.429](https://doi.org/10.1038/jid.2013.429)

## Content

1. J Invest Dermatol. 2014 Apr;134(4):1067-1074. doi: 10.1038/jid.2013.429. Epub 
2013 Oct 15.

NRAS mutation is the sole recurrent somatic mutation in large congenital 
melanocytic nevi.

Charbel C(1), Fontaine RH(1), Malouf GG(2), Picard A(3), Kadlub N(3), El-Murr 
N(1), How-Kit A(4), Su X(5), Coulomb-L'Hermine A(6), Tost J(7), Mourah S(8), 
Aractingi S(9), Guégan S(10).

Author information:
(1)Saint Antoine Research Center, U938, Institut National de la Santé et de la 
Recherche Médicale (INSERM), Paris, France; Université Pierre et Marie 
Curie-Paris VI, Paris, France.
(2)Université Pierre et Marie Curie-Paris VI, Paris, France; Department of 
Medical Oncology, Groupe Hospitalier Pitié-Salpêtrière, Assistance 
Publique-Hôpitaux de Paris (AP-HP), Paris, France.
(3)Université Pierre et Marie Curie-Paris VI, Paris, France; Department of 
Maxillofacial and Plastic Surgery, Hôpital Necker, APHP, Paris, France.
(4)Laboratory for Functional Genomics, Fondation Jean Dausset-CEPH, Paris, 
France.
(5)Department of Bioinformatics and Computational Biology, University of Texas 
MD Anderson Cancer Center, Houston, Texas, USA.
(6)Université Pierre et Marie Curie-Paris VI, Paris, France; Department of 
Pathology, Hôpital Trousseau, APHP, Paris, France.
(7)Laboratory for Functional Genomics, Fondation Jean Dausset-CEPH, Paris, 
France; Laboratory for Epigenetics and Environment, Centre National de 
Génotypage, CEA-Institut de Génomique, Evry, France.
(8)Laboratory of Pharmacology-Genetics, Hôpital Saint-Louis, APHP, Paris, 
France.
(9)Saint Antoine Research Center, U938, Institut National de la Santé et de la 
Recherche Médicale (INSERM), Paris, France; Université René Descartes-Paris V, 
Paris, France; Department of Dermatology, Hôpital Cochin, APHP, Paris, France.
(10)Saint Antoine Research Center, U938, Institut National de la Santé et de la 
Recherche Médicale (INSERM), Paris, France; Université Pierre et Marie 
Curie-Paris VI, Paris, France; Department of Dermatology, Hôpital Tenon, APHP, 
Paris, France. Electronic address: sarah.guegan@tnn.aphp.fr.

Comment in
    J Invest Dermatol. 2014 Apr;134(4):879-882. doi: 10.1038/jid.2013.531.

Congenital melanocytic nevus (CMN) is a particular melanocytic in utero 
proliferation characterized by an increased risk of melanoma transformation 
during infancy or adulthood. NRAS and BRAF mutations have consistently been 
reported in CMN samples, but until recently results have been contradictory. We 
therefore studied a series of large and giant CMNs and compared them with small 
and medium CMNs using Sanger sequencing, pyrosequencing, high-resolution melting 
analysis, and mutation enrichment by an enhanced version of ice-COLD-PCR. 
Large-giant CMNs displayed NRAS mutations in 94.7% of cases (18/19). At that 
point, the role of additional mutations in CMN pathogenesis had to be 
investigated. We therefore performed exome sequencing on five specimens of 
large-giant nevi. The results showed that NRAS mutation was the sole recurrent 
somatic event found in such melanocytic proliferations. The genetic profile of 
small-medium CMNs was significantly different, with 70% of cases bearing NRAS 
mutations and 30% showing BRAF mutations. These findings strongly suggest that 
NRAS mutations are sufficient to drive melanocytic benign proliferations in 
utero.

DOI: 10.1038/jid.2013.429
PMID: 24129063 [Indexed for MEDLINE]